Skip to content
Login
Search:
CROI Conference
CROI ConferenceCROI Conference
  • About CROI
    • CROI 2027 Important Dates
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • CROI Abstract Categories
    • Abstract Guidelines and Submission
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Who Can Attend
    • Letter Of Invitation (For Visa And Other Purposes)
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
  • Program
    • CROI 2027 Program
    • Our Voices
    • Media
    • Embargo Policies And Press Release Policies
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • About CROI
    • CROI 2026 Preliminary Important Dates and Deadlines
    • CROI Foundation
    • Scientific Program Committee and Community Liaison Subcommittee
    • Funding and Grant Support
    • IAS-USA
    • Policies, Website, and Copyrights
    • Illustrations of HIV, HCV, and SARS-CoV-2 Viruses
    • Contact Us
  • Abstracts
    • Abstract Guidelines and Submission
    • CROI Abstract Categories
    • Assignment of Abstract Copyright to CROI
    • People-First Language and the Use of Appropriate Terminology
  • Presenters
    • Invited Presenters and Moderators
    • Oral Abstract Presentation Guidelines
    • Poster Presentation Guidelines
    • Themed Discussion Guidelines
    • Plain Language Summaries: A Mile-High View at CROI 2026
    • People-First Language and the Use of Appropriate Terminology
    • Letter Of Invitation (For Visa And Other Purposes)
  • Attendees
    • Registration
    • Who Can Attend
    • Media Accreditation and Registration
    • Affiliated and Proximate Activities
    • Frequently Asked Questions
  • Scholarships
    • New Researcher Scholarship
    • International Researcher Scholarship
    • Community Educator and Mentor Scholarships
    • Scholarship Travel
  • Program
    • CROI 2027 Program
    • CROI 2026 Resources
    • Our Voices
    • Media
    • Resources From Prior Years
    • Webcasts
    • Abstracts and ePoster Archive
    • CROI Issues of TAM
  • CROI 2027 Important Dates

Search Results for: node/PEP: Remember Me?

1281 – Increased Knowledge and Use of Doxycycline Postexposure Prophylaxis in King County, Washington

By Jimmy He PharmD, DScMarch 20, 2025

Background Following evidence of doxycycline postexposure prophylaxis (doxyPEP) efficacy to prevent chlamydia, gonorrhea and syphilis among men and transgender women who have sex with men, Public Health – Seattle &…

PROFILING ANTIBODY CROSS-REACTIVITY AMONG SIV ISOLATES USING A PEPTIDE MICROARRAY

By Enthusiast Inc MDMarch 6, 2019

…peptide arrays enable the determination of antibody reactivity to as many as six million peptides in a single assay. Identification of antibodies capable of binding a wide variety of HIV…

287 – Mutation-Constrained Regions of HIV-1 Proteins Elicit Antigen-Specific Effector CD8 T-Cell Responses

By Jimmy He PharmD, DScMarch 31, 2026

…immunogenicity of these IMAP-peptides, we assessed the CD8 T cell responses to the total HIV-1 IMAP peptide pool (182 peptides) and IMAP-peptides pooled by HIV-1 protein. Methods We collected peripheral blood…

Rilpivirine-Emtricitabine-Tenofovir for HIV Nonoccupational Postexposure Prophylaxis

By Enthusiast Inc MDFebruary 27, 2015

Background: CDC recommends 3-drug post-exposure prophylaxis (PEP) with emtricitabine-tenofovir disoproxil fumarate (FTC-TDF) plus raltegravir (RAL) for 28 days. But in one non-occupational (N)PEP study, FTC-TDF-RAL adherence was imperfect (only 52%…

Rilpivirine-Emtricitabine-Tenofovir for HIV Nonoccupational Postexposure Prophylaxis

By Enthusiast Inc MDFebruary 27, 2015

Background: CDC recommends 3-drug post-exposure prophylaxis (PEP) with emtricitabine-tenofovir disoproxil fumarate (FTC-TDF) plus raltegravir (RAL) for 28 days. But in one non-occupational (N)PEP study, FTC-TDF-RAL adherence was imperfect (only 52%…

The HIV Env Signal Peptide Impacts the Glycosylation and Antigenicity of gp120

By Enthusiast Inc MDFebruary 16, 2016

…transmission signature has been identified in the signal peptide of Env. This signature involves the over-representation of basic residues at a specific position in the signal peptide. We investigated the…

POSTEXPOSURE PROPHYLAXIS NONCOMPLETION AND NONCONDOM USE IN FRANCE, 2004-2017

By Enthusiast Inc MDMarch 7, 2019

…exposures). PEP regimens varied among time (Figure). Overall, 20% of individuals discontinued their PEP regimen within 20 days. Age (OR, 0.87 per 10-years increment [0.83-0.92]), MSM (OR, 0.59 [0.47-0.73]), intercourse…

LOW PREVALENCE OF HEPATITIS C VIRUS AMONG NYC MSM INITIATING PrEP AND PEP, 2016-2017

By Enthusiast Inc MDMarch 5, 2018

…is obtained per New York State PrEP/PEP Guidelines. Using electronic medical record data from the PrEP/PEP initiation visit, we examined HCV testing, demographics, incident sexually transmitted infections, and reported sexual…

Potent Cross-Reactive HIV-1 Neutralization in Fusion Peptide-Primed SHIV-Infected Macaques

By Jimmy He PharmD, DScMarch 6, 2024

…breadth on a cross-clade panel of 208 strains with geometric mean ID50 titers of ~100, a level of potency recently shown to protect against mucosal SHIV challenge from fusion peptide-directed…

Role of Sulfhydryl in Causing Lytic Inactivation of HIV- 1 by Env Targeting Peptide Triazole Thiols

By Enthusiast Inc MDSeptember 29, 2014

…from the virus lumen. The prototype peptide triazole thiol KR-13 (R-I-N-N-I-X-W-S-E-A-M-M-βAQ-βA-C-CONH2, X= ferrocenyltriazole-Pro) causes p24 release, however KR-13b (C-terminal SH capped by acetomidomethyl) inhibited cell infection but did not cause…

←1
2345
…678910…
111213141516171819202122232425262728293031323334353637383940414243444546474849505152535455565758596061626364656667686970717273747576777879808182
83→
Copyright © 2026 CROI Foundation/IAS-USA. All Rights Reserved.
Website by Enthusiast, Inc.
  • About CROI
  • Presenters
  • Abstracts
  • Scholarships
  • Program
Footer Menu
Go to Top